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TNFa, tumor necrosis factor a.Behçet’s disease is a chronic, relapsing inﬂammatory disease that can involve the mouth, skin,
eyes, genitals, and intestines. Active intestinal Behçet’s disease can be complicated by gastro-
intestinal (GI) bleeding and perforation. We performed a multicenter, open-label, uncontrolled
study to evaluate the efﬁcacy and safety of adalimumab, a fully human monoclonal antibody
against tumor necrosis factor a, in patients with intestinal Behçet’s disease who were refractory
to corticosteroid and/or immunomodulator therapies.METHODS: The study was conducted at 12 sites in Japan, from November 2010 through October 2012.
Twenty patients were given 160 mg adalimumab at the start of the study and 80 mg 2 weeks
later, followed by 40 mg every other week for 52 weeks; for some patients, the dose was
increased to 80 mg every other week. A composite efﬁcacy index, combining GI symptom and
endoscopic assessments, was used to evaluate efﬁcacy. The primary efﬁcacy end point was the
percentage of patients with scores of 1 or lower for GI symptom and endoscopic assessments at
week 24. Secondary end points included complete remission and resolution of non-GI Behçet’s-
related symptoms.RESULTS: Nine patients (45%) had GI symptom and endoscopic assessment scores of 1 or lower at week
24 of treatment, and 12 patients (60%) had these scores by week 52. Four patients (20%)
achieved complete remission at weeks 24 and 52. Individual global GI symptom and endoscopic
scores improved for most patients at weeks 24 and 52. Two thirds of patients with oral aph-
thous ulcers, skin symptoms, and genital ulcers, and 88% of patients with erythema nodosum
had complete resolution of these conditions at week 52. A total of 9 of 13 patients (69%) taking
steroids at baseline were able to taper (n [ 1) or completely discontinue steroids (n [ 8)
during the study. No new safety signals were observed.CONCLUSIONS: Adalimumab is a potentially effective treatment for intestinal Behçet’s disease in Japanese
patients who are refractory to conventional treatments. ClinicalTrials.gov number:
NCT01243671.Keywords: Autoimmunity; Anti-TNF Agent; Endoscopy; Japan.r: AAA, anti-adalimumab antibodies; ADA,
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May 2015 Adalimumab for Intestinal BD 941Behçet’s disease (BD) is a chronic, relapsing in-ﬂammatory disease involving multiple organs,
including the mouth, skin, eyes, and genitals.1 Approxi-
mately 15% to 20% of patients with BD develop intes-
tinal ulcers,2 which are associated with symptoms of
abdominal pain and diarrhea. Deep intestinal ulcerations
pose a risk of perforation and bleeding.
BD prevalence is highest in countries along the Silk
Road, a belt-like region running from the Mediterranean
through the Middle East into China and Japan.1 In Japan,
the estimated prevalence is 13 to 20 per 100,000,
whereas in the United States and the United Kingdom it
is 10-fold lower.3 The average age of onset is 18 to 40
years of age,1 and intestinal BD affects more males than
females.4 BD is treated conventionally with corticoste-
roids and/or nonbiologic immunomodulators, including
thiopurines; however, many patients fail to respond to
these treatments or become steroid-dependent.5,6 For
refractory patients, surgical resection of the intestine to
address bleeding or bowel perforation often is required.7
The postoperative recurrence rate for intestinal ulcers
remains high,8 however, highlighting a need for treat-
ments that can maintain long-term disease remission.
Intestinal BD is associated with excess production of
inﬂammatory cytokines, including tumor necrosis factor
a (TNFa).9 Inﬂiximab, a chimeric TNFa inhibitor, is
approved in Japan for the treatment of uveitis in patients
with BD.10 Clinical studies have reported the efﬁcacy of
adalimumab (ADA),11 a fully humananti-TNFamonoclonal
antibody, and inﬂiximab for intestinal BD.5,12–19 However,
no larger-scale, long-term clinical trials have examined the
efﬁcacy of anti-TNFa therapies for the treatment of intes-
tinal BD.20 Adalimumab is widely approved for adult
Crohn’s disease (CD), adult ulcerative colitis, pediatric CD
(Europe), and other immune-mediated inﬂammatory dis-
orders.21,22 Here, we present the 52-week results of a
clinical study of ADA in Japanese patients with intestinal
BD. Because there was no widely used end point for
assessment of signs and symptoms of BD at the time this
study was conceived, a novel composite efﬁcacy indexwas
developed that combines evaluations of both gastrointes-
tinal (GI) symptoms and endoscopic appearance.Methods
Study Design
This 52-week, phase 3, multicenter, open-label, un-
controlled study evaluated the efﬁcacy, safety, and
pharmacokinetics of ADA in Japanese patients with
active intestinal BD who were refractory to conventional
therapies. A novel composite disease activity index was
developed (Figure 1A) that consisted of 2 separate
scoring components: (1) patient evaluation of the global
activity of GI symptoms in the 2 weeks before each study
visit on a 4-point scale, and (2) change in ulcer size since
baseline endoscopic assessment. For the endoscopicefﬁcacy assessment, the size of the largest ileocecal ulcer
was compared with its size at screening. Ulcer size was
evaluated via photography with a comparative object (eg,
biopsy forceps) and scored on the basis of change in the
longest ulcer diameter using a 4-point scale. If a new
ulcer larger than the index ulcer developed, the diameter
of the new ulcer was compared with that of the index
ulcer during screening.
The study was conducted at 12 sites in Japan. The
institutional review board of each center approved the
protocol, and each patient provided written informed
consent. For patients aged 19 and younger, written
consent also was provided by the patient’s guardian.
Inclusion criteria. Disease activity for study inclusion
was based on the global GI symptom score. Patients aged
15 years and older with BD, an ileocecal ulcer 1 cm or
larger in diameter, and a baseline global GI symptom
score of 3 or higher were eligible. Patients were re-
fractory to stable treatment with corticosteroids or im-
munomodulators, or had failed to taper corticosteroids
during the 12 months before screening. Patients with
intolerance or loss of response to prior inﬂiximab were
eligible. Additional inclusion criteria are described in the
Supplementary Methods section.
Exclusion criteria. Exclusion criteria included Crohn’s
disease, current or prior active tuberculosis, previous
ADA treatment, or history of ileocecal resection. Patients
with evidence of latent tuberculosis were to complete a
21-day or longer course of tuberculosis prophylaxis
before receiving ADA. Evidence of dysplasia or malig-
nancy at screening colonoscopy or a history of cancer,
other than a successfully treated nonmetastatic cuta-
neous squamous or basal cell carcinoma and/or localized
carcinoma in situ of the cervix, was exclusionary.
Additional exclusion criteria are described in the
Supplementary Methods section.
Treatment administration. All patients received in-
duction treatment with ADA 160 mg at week 0 (baseline)
and 80 mg at week 2, and maintenance treatment with 40
mg every other week (eow) from weeks 4 to 50
(Figure 1B). Study drug was administered by a physician
or nurse through week 8. After week 8, patients who were
willing could self-administer the study drug (or have a
family member administer the injection). Doses of
BD medications except corticosteroids, colchicine, and
enteral nutrition (which could be tapered at the in-
vestigator’s discretion fromweek 8 in patients responding
to ADA treatment) were maintained stably through week
24 unless treatment-related, moderate-to-severe toxic-
ities arose. Initiation, discontinuation, or change in dosage
of concomitant treatments was permitted after week 24.
From week 8, patients with inadequate response or
disease ﬂare (both deﬁnitions are outlined in the
Supplementary Methods section and were based on
global symptom or endoscopic appearance scores) could
dose-escalate to ADA 80 mg eow. Patients with inade-
quate response or disease ﬂare after dose escalation
were withdrawn from the study.
Figure 1. (A) Evaluation criteria for global GI symptom and endoscopic assessment scores. A combination of scores is used to
characterize disease state after treatment (complete remission, marked improvement, improvement, and no change/aggra-
vated). (B) Study design. (C) Patient disposition. IC, informed consent.
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Global GI symptom scores were assessed every 4
weeks and endoscopic assessments were conducted at
weeks 8/12, 24, and 52/early termination (Figure 1B). At
each study visit, patients also assessed the degree that 3
individual GI symptoms (diarrhea, pain, and abdominal
discomfort/bloating) affected daily life using the same 4-
point scale as the global GI symptom score. In addition, the
degree to which 4 other BD-related symptoms affected
daily life (oral aphthous ulcers, erythema nodosum, uve-
itis, and genital ulcers) over the previous 4 weeks was
recorded using a 4-point scale. Details of these assess-
ments are located in the Supplementary Methods section.
Fecal calprotectin level was not assessed.
The primary efﬁcacy evaluations of the study were
based on categorization of patients as having no change/
aggravated, improvement, marked improvement (MI),
and complete remission using the composite index
(Figure 1A). The primary end point was the proportion of
patients with MI (values 1 for both the global GI
symptom and endoscopic assessment scores) at week 24.
This end point included patients with complete remis-
sion, deﬁned as global GI symptom and endoscopic
scores of 0. Major secondary end points included MI atweek 52, complete remission at weeks 24/52, and global
GI symptom score and endoscopic appearance score of
0 or 1 or less at weeks 24/52. Additional secondary end
points at weeks 24 and 52 included individual GI
symptom scores of 1 or less or improvement by 1 or
more points; improvement by 1 or more points in global
GI symptom score; complete disappearance of non-GI BD
symptoms; and change from baseline in serum C-reactive
protein (CRP) levels. Secondary quality-of-life end points
included changes from baseline in the Inﬂammatory
Bowel Disease Questionnaire (IBDQ) (used under license
from McMaster University)23 and the Short-Form 36
Health Survey.24Safety Evaluations
Patients were monitored for treatment-emergent
adverse events (AEs) every 2 weeks. Physical examina-
tions and clinical laboratory tests (hematology, clinical
chemistry, and urinalysis) were conducted at screening
and every 4 weeks. All AEs from time of study drug
administration until 70 days after discontinuation
(regardless of investigator-assigned causality) were
reported.
Table 1. Patient Demographics and Baseline Characteristics
Characteristic FAS (n ¼ 20)
Male sex, n (%) 10 (50.0)
Mean age  SD, y 42.4  13.3
Weight, kg
Mean  SD 55.8  8.4
Range 40.0–78.0
Tobacco, nonsmoker, n (%) 8 (40.0)
Alcohol, nondrinker, n (%) 8 (40.0)
Duration of intestinal BD, y
Mean  SD 4.6  7.2
Range 0.1–31.1
Non-GI BD symptoms, n (%) 20 (100)
Oral aphthous ulcer 15 (75)
Erythema nodosum 8 (40)
Uveitis 0
Genital ulcer 3 (15)
Global assessment of GI symptom score
3 15 (75)
4 5 (25)
Number of ileocecal ulcers
1 10 (50.0)
2 4 (20.0)
3 2 (10.0)
4 0
5 4 (20.0)
Longest diameter of ileocecal open ulcer
1 to <2 cm 8 (40.0)
2 to <3 cm 5 (25.0)
3 cm 7 (35.0)
IBDQ score, mean  SD 140.5  36.2
SF-36
Physical component summary 41.8  5.7
Mental component summary 34.6  12.4
Prior inﬂiximab use, n (%) 3 (15.0)
Mean CRP level,a mg/dL 0.8
Concomitant BD medication,b n (%)
Corticosteroidsc 13 (65.0)
5-Aminosalicylic acid 13 (65.0)
Immunomodulatorsd 3 (15.0)
FAS, full analysis set; SF-36, Short-Form 36 Health Survey.
aNormal range was 0.3 mg/dL.
bMedications ongoing after the ﬁrst study drug dose.
cPrednisolone (mean daily dose, 7.1 mg/d; range, 2.5–20 mg) was the only
reported concomitant corticosteroid used.
dImmunomodulators were deﬁned as methotrexate, azathioprine, or mercap-
topurine. All 3 patients were taking azathioprine.
Figure 2. Percentage of patients (95% CI) with marked
improvement or complete remission at weeks 8/12, week 24
(primary end point), and week 52. CI, conﬁdence interval.
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Assessments
Blood samples for serum ADA concentration deter-
mination were obtained at baseline and before ADA in-
jection at weeks 2, 4, 8, 16, 24, 36, and 52. Serum
concentration of anti-ADA antibodies (AAAs) was deter-
mined at baseline and weeks 8, 16, 24, 36, and 52.
Adalimumab and AAA concentrations were determined
using the sponsor’s validated enzyme-linked immuno-
sorbent assays at each time point and summarized using
descriptive statistics as described previously.25 Samples
were considered to be AAAþ if the AAA concentration
was greater than 20 ng/mL in undiluted serum. Patientswere considered AAAþ if they had at least 1 AAAþ
sample.
Statistical Analyses
Discrete variables were summarized by counts and
percentages with 95% conﬁdence intervals, and contin-
uous variables were summarized by descriptive statis-
tics. Missing data were imputed using nonresponder
imputation (NRI) for categoric variables and last obser-
vation carried forward (LOCF) or observed case for
continuous variables. On the basis of previously
observed remission rates after ADA induction treatment
in Japanese patients with CD25 and a sample size of 20
patients, a threshold for determining the efﬁcacy of ADA
was set at 25% of patients achieving MI. Patients who
dose-escalated to 80 mg eow were included in the
analysis.
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
Results
Disposition and Demographics
Patient demographics and baseline characteristics are
described in Table 1 and Figure 1C. Twenty patients were
enrolled and treated (Figure 1C) and represent the full
analysis set for efﬁcacy and safety analyses. Seventeen
patients completed the study; 2 patients discontinued
because of AEs, and 1 patient voluntarily discontinued for
personal reasons that were not drug-related.
Efﬁcacy
Nine patients (45%) achieved MI at week 24, and 12
patients (60%) achieved MI at week 52 (NRI) (Figure 2).
Complete remission was achieved in 4 patients (20%) at
week 24 and week 52 (NRI) (Figure 2). Improvement of
global GI symptoms was observed as early as week 4,
944 Tanida et al Clinical Gastroenterology and Hepatology Vol. 13, No. 5with 5 patients (25%) reporting scores of 0, and 11
patients (55%) reporting scores of 1 or less (NRI)
(Figure 3A and Supplementary Table 1). Improvement in
the endoscopic appearance of ulcers was observed early.
Eight patients (40%) had an endoscopic assessment
score of 1 or less at week 8/12; this end point was
achieved by 65% of patients at week 52 (NRI) (Figure 3B
and C). No patient reported worsening of the global GI
symptom score at week 52 (LOCF) (Supplementary
Figure 1A), and the endoscopic score at week 8/12Figure 3. Percentage of patients (95% CI) achieving secondary
symptom score (NRI) and (B) endoscopic assessment score; (C
at week 24 (right); (D) concordance of global assessment of GI s
observed); (E) concordance of values of 0 for global assessment
resolution of non-GI BD symptoms (NRI). CI, conﬁdence intervaremained stable or improved by week 52 for all but 1
patient (LOCF) (Supplementary Figure 1B). There was
good concordance between the observed symptomatic
and endoscopic improvement at weeks 24 and 52
(Figure 3D); the concordance of values of 0 for both
scores was lower (Figure 3E).
Treatment with ADA also was associated with rapid
resolution of non-GI BD symptoms. Two-thirds of pa-
tients with oral aphthous ulcers and genital ulcers and
88% of patients with erythema nodosum had completeefﬁcacy end points, including improvement in (A) global GI
) representative patient’s intestinal ulcers at baseline (left) and
ymptoms and endoscopic assessment scores of 1 or less (as
of GI symptoms and endoscopic assessment scores; and (F)
l.
Table 3.Overview of Treatment-Emergent Adverse Events:
Full Efﬁcacy Analysis Set
AE, n (%)
Week 24
(n ¼ 20)
Week 52
(n ¼ 20)
Any AE 17 (85) 20 (100)
May 2015 Adalimumab for Intestinal BD 945resolution of these conditions at week 52 (NRI)
(Figure 3F). Mean serum CRP levels decreased after ADA
treatment; the mean decrease from baseline (LOCF)
ranged from -0.1 mg/dL (at week 12) to -0.7 mg/dL (at
week 48). At week 24, the mean observed serum CRP
level was lower in patients with MI (n ¼ 9; 0.3 mg/dL)
than in patients without MI (n ¼ 9; 0.7 mg/dL). The
corresponding CRP levels at week 52 were 0.1 mg/dL
(n ¼ 12) and 1.8 mg/dL (n ¼ 8) for patients with and
without MI, respectively.
Six patients escalated to ADA 80 mg eow because of
an inadequate response (n ¼ 4) or disease ﬂare (n ¼ 2)
during the study. At week 52, 1 patient achieved MI, 1
patient had a global GI symptom score of 1 or less, and a
third patient had an endoscopic score of 1 or less.
Adalimumab treatment resulted in mean improve-
ments exceeding the thresholds that were deemed clin-
ically meaningful for both the IBDQ23 (>16 points) and
Short-Form 36 Health Survey24 (3 points) quality-of-
life measures (Table 2).
Concomitant medication tapering and dis-
continuation. Nine of the 13 patients receiving concom-
itant steroids at baseline tapered their dose, and 8
patients discontinued steroids altogether by week 52. Of
these 8 patients, 5 achieved MI, including 3 patients with
complete remission. The patient who tapered but did not
discontinue steroid use went from prednisolone 10 mg at
baseline to 6 mg at week 52 and achieved MI. No patient
required steroid dose escalation or initiated new steroid
treatment during the study.
Pharmacokinetics
Observed mean serum ADA concentrations remained
stable during the maintenance period (weeks 16–52)
(Supplementary Table 2). Dose escalation to 80 mg eow
resulted in approximately twice the serum ADA concen-
tration. The mean serum ADA concentrations for patients
at week 52/early termination were as follows: patients
with complete remission, 8.5 mg/mL (n ¼ 4, all receiving
40 mg eow dosing); MI but not complete remission, 14.6
mg/mL (n ¼ 8, 1 receiving 80 mg eow dosing); and non-
responders, 17.0 mg/mL (n ¼ 6, 4 receiving 80 mg eow
dosing; 1 patient who discontinued the study before week
52 and had a serum ADA concentration collected at studyTable 2.Quality-of-Life Variables at Weeks 24 and 52: FAS
and LOCF
Efﬁcacy variables,
mean change from
baseline  SD
Week 8
(n ¼ 20)
Week 24
(n ¼ 20)
Week 52
(n ¼ 20)
IBDQ 34.0  37.8 37.1  40.0 41.2  41.9
SF-36 summary score
Physical 6.2  7.4 7.5  7.2 9.0  8.4
Mental 7.0  11.1 8.9  12.9 9.0  13.3
FAS, full analysis set; SF-36, Short-Form 36 Health Survey.day 351 is included in this group, and week 52 ADA
concentrations were not available for the remaining 2
patients who prematurely terminated study participa-
tion). One patient was AAAþ (with a serum ADA con-
centration of 0) at weeks 36 and 52; this patient achieved
MI at both weeks 24 and 52. The AAAþ patient did not
dose-escalate and was receiving a concomitant immuno-
modulator (azathioprine) at week 24, which was dis-
continued on study day 230 (approximately week 33).
Safety
No new safety signals were observed, and no deaths
occurred. There were no cases of malignancy, congestive
heart failure, demyelination, or lupus-like syndrome.
Through week 52, 25% of patients experienced an AE
that was assessed as possibly or probably related to
study drug (Table 3). The most frequent treatment-
emergent AEs were nasopharyngitis (n ¼ 9; 45%) and
diarrhea, arthropod sting (not considered to be related to
study drug), and cough (n ¼ 3; 15% each). Four of the 6
patients who dose-escalated experienced an infection
after dose escalation; none of these patients experienced
an infection before dose escalation.
Two patients withdrew from the study because of
AEs. One patient experienced a stenotic terminal ileal
obstruction on day 7, which was assessed as probably
not related to ADA. The patient received endoscopic
balloon dilation and improved. The other patient with-
drew because of worsening Behçet’s syndrome symp-
toms after ADA dose escalation; this AE was assessed as
not related to study drug.Discussion
The results of this clinical trial show that ADA
reduced GI symptoms and led to intestinal ulcer healingAt least possibly drug related 5 (25) 5 (25)
Serious 1 (5) 1 (5)
Leading to early discontinuation 2 (10) 2 (10)
AE of interest
Infection 9 (45) 14 (70)
Injection site reaction 2 (10) 2 (10)
Noncutaneous vasculitis 2 (10) 3 (15)
Tuberculosis 0 1 (5)
Hepatic event 2 (10) 3 (15)
Allergic reaction 1 (5) 2 (10)
Intestinal stricture related 1 (5) 1 (5)
Increased ALT levels 1 (5) 1 (5)
ALT, alanine aminotransferase.
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conventional treatment. Forty-ﬁve percent of patients
achieved the study’s primary end point (MI at week 24),
exceeding the prespeciﬁed threshold for study success.
Complete ulcer healing was observed in the majority of
patients at week 52. Adalimumab treatment also induced
complete remission in 20% of patients at week 24, which
was maintained through week 52. Treatment with ADA
led to rapid improvement in non-GI BD symptoms at
week 4. The mean serum levels of CRP decreased with
ADA treatment, indicating biologic anti-inﬂammatory
activity. Pharmacokinetic data showed similar serum
ADA concentrations to those observed previously for a
similar dosing schedule in Japanese patients,25 and the
rate of immunogenicity was low. An exposure-response
relationship was not evident; however, the relevance of
this ﬁnding was limited by the small number of patients
in each response category.
Adalimumab treatment also resulted in improvement
of quality of life. The majority of patients receiving cor-
ticosteroids at baseline were able to taper or discontinue
use over the course of the study, with 8 of 9 patients
(89%) completely discontinuing steroids at the end of
the study. Adalimumab treatment was well tolerated. All
reported AEs were similar to those observed in other
ADA clinical trials.26–29
There is no consensus for intestinal BD management.
Surgical resection is often a short-term solution because
many patients experience recurrence of intestinal ul-
cerations.8 On the basis of case reports,5,11,12,14–18,20 a
Japanese expert panel recently recommended anti-TNFa
therapies for intestinal BD.20 Our study provides further
support for this recommendation.
Currently, there is no widely accepted clinical index
for the assessment of intestinal BD activity, which is
complicated by the relatively rare nature of the disease.
A new intestinal BD activity index (the disease activity
index for intestinal Behçet’s disease) based on patient-
reported GI symptoms and other factors (fever, extra-
intestinal manifestations, abdominal mass, and intestinal
complications) recently was proposed; however, this
method does not include endoscopic assessment.30
Endoscopic assessment is nonetheless an important
objective measure for evaluation of intestinal BD, espe-
cially in an unblinded trial in which patient-reported
symptoms may be inﬂuenced by the knowledge of
treatment allocation. In addition, the correlation between
endoscopic severity and the disease activity index for
intestinal Behçet’s disease was found to be weak in 1
series.31 Our report describes a novel index that com-
bines separate scores for global symptom severity and
intestinal ulcer evaluation. The majority of patients in the
study with a global GI symptom score of 1 or less also
had an endoscopic assessment score of 1 or less,
although the concordance for values of 0 for both scores
was lower (Figure 3E). This index can be used to track
disease activity and therapeutic efﬁcacy in future studies
of intestinal BD; however, because the endoscopicassessment only assesses changes in ulcer size, it can be
used only to measure changes in disease activity.8
Limitations of this study included its relatively small
sample size and lack of placebo control, which have the
potential to bias the ﬁndings. However, given the small
number of patients with intestinal BD who have failed
conventional therapy, it was not feasible to conduct a
large placebo-controlled study. A further limitation was
the use of an unvalidated composite disease activity index,
and the lack of validation of the study’s end point. For
simplicity of evaluation and because changes in ulcer size
were believed to be similar for all ulcerswhenmore than 1
ulcer was present, the endoscopic change index was
limited to the assessment of the largest ileocecal ulcer
present during screening. This approach neglected eval-
uation of changes in other ulcers, which could limit the
detection of increased inﬂammation occurring outside of
the index ulcer. In addition, the endoscopic index did not
include evaluation or weightings for ulcer depth or shape,
a count of the number of ulcers, or assessment of absolute
ulcer size, all of which may be related to intestinal BD
clinical activity, as suggested by a recent analysis.31
Additional evaluation of this and other available intesti-
nal BD activity indices, including consideration of incor-
poration of objective biomarkers, is warranted. Finally,
the IBDQ results may not be directly applicable to patients
with intestinal BD and should be interpreted with caution.
Together, these data show that a novel composite
index, composed of an assessment of GI symptoms and
changes in intestinal ulceration, is useful for tracking
intestinal BD progression or improvement. This study
showed that ADA is safe and effective for the treatment
of intestinal BD in patients who are refractory to con-
ventional therapies.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://dx.doi.org/10.1016/j.cgh.2014.08.042.References
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Inclusion Criteria
Patients were included if they received (or had failure
or intolerance to) at least 1 of the following treatments:
prednisolone 20 mg/d or equivalent for 14 days,
prednisolone 5 but <20 mg/d for 40 days, azathio-
prine 50 mg/d, or 6-mercaptopurine 30 mg/d; or a
dose of an immunomodulator that is the highest toler-
ated by the patient (eg, as a result of leukopenia,
increased liver enzyme levels, or nausea) for 90 days.
Stable dosing of corticosteroids or immunomodulators
for 14 and 28 days, respectively, before baseline was
required for patient inclusion. For patients receiving
both oral corticosteroids and immunomodulators, only 1
of the drugs needed to meet the earlier-described
criteria.
Exclusion Criteria
Patients were excluded if they had a history of
chronic or active hepatitis B or C infection, human im-
munodeﬁciency virus, listeriosis, immunodeﬁciency
syndrome, histoplasmosis, or chronic recurring in-
fections. Patients with a history of cyclosporine, tacroli-
mus, or mycophenolate mofetil use within 28 days of
baseline were excluded, as were those who discontinued
5-aminosalicylic acid, colchicine, or enteral nutrition
within 28 days of baseline. Patients receiving more than
1200 kcal/d of enteral nutrition were excluded. Patients
taking 5-aminosalicylic acid, colchicine, or enteralnutrition (1200 kcal/d) were eligible if their dose had
been stable for at least 28 days before baseline.
Efﬁcacy Assessments
Physician assessment of non-GI BD symptoms was
conducted using the following criteria: for assessment of
uveitis, grades 0 to 3 indicated the number of inﬂamma-
tory eye events occurring during the previous 4 weeks;
and for oral aphthous ulcers, genital ulcers, and erythema
nodosum, scores of 0 to 3 were used to describe the de-
gree of symptoms over the previous 4 weeks, with
0 indicating no symptoms, 1 describing symptoms
occurring for fewer than 2 weeks, 2 describing symptoms
occurring for 2 weeks or longer, and 3 describing symp-
toms occurring during most of the 4-week interval.
Dose-Escalation Criteria
For the purposes of dose escalation, inadequate
response and disease ﬂare were deﬁned as follows:
inadequate response was deﬁned as a global GI symptom
score of 3 or higher on 2 consecutive visits 14 days apart,
or lack of reduction or expansion of a patient’s evaluated
ileocecal ulcer compared with the size observed during
the screening endoscopy; disease ﬂare was deﬁned as a
global GI symptom score of 2 or higher on 2 consecutive
visits at least 14 days apart, after achievement of global GI
symptom score of 1 or less during the study. Disease ﬂare
also was deﬁned as the expansion of the largest ileocecal
ulcer to more than half of the longest dimension at
baseline after the ulcer previously had decreased to one
quarter or less of the longest dimension at baseline.
Supplementary Figure 1. Individual changes in (A) global
assessment of GI symptom score and (B) endoscopic
assessment score by patient. Arrows indicate direction of
change during the study. Circles are superimposed for pa-
tients for whom there was no score change. One patient did
not have a week 8/12 endoscopy and was not included in the
second graph.
Supplementary Table 1.Global GI Symptom Score By Visit
Global assessment of GI
symptoms, n (%) 0 1 Improvement 1
Week 4 5 (25.0) 11 (55.0) 18 (90.0)
Week 8 8 (40.0) 13 (65.0) 15 (75.0)
Week 12 8 (20.0) 12 (60.0) 16 (80.0)
Week 24 9 (45.0) 13 (65.0) 16 (80.0)
Week 52 9 (45.0) 16 (80.0) 18 (90.0)
NOTE. FAS (N ¼ 20), NRI.
FAS, full analysis set.
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Supplementary Table 2.Mean Serum Adalimumab Trough Concentrations
Week 2 Week 4 Week 8 Week 16 Week 24 Week 36 Week 52
All patients 13.7  3.7 (20) 13.1  4.6 (19) 10.4  4.3 (19) 9.7  4.3 (18) 10.5  5.2 (18) 13.1  6.4 (18) 13.8  7.4 (17)
Remained on
40 mg eow
14.1  3.8 (15) 13.6  4.0 (14) 11.0  4.0 (14) 8.7  3.8 (14) 9.1  4.5 (14) 10.4  4.8 (13) 11.6  6.3 (13)
Dose escalated to
80 mg eow
12.2  3.1 (5) 11.7  6.3 (5) 8.8  5.2 (5) 13.2  5.0 (4) 15.6  4.7 (4) 20.0  4.6 (5) 20.7  7.0 (4)
NOTE. Values are shown as mg/mL  SD (Nnmiss).
Nnmiss, number of nonmissing observations.
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